GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » Owner Earnings per Share (TTM)

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Owner Earnings per Share (TTM) : (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Anhui Wanbang Pharmaceutical Technology Co does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for Anhui Wanbang Pharmaceutical Technology Co's Owner Earnings per Share (TTM) or its related term are showing as below:

SZSE:301520' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0   Med: 0   Max: 53.12
Current: 37.17


During the past 6 years, the highest Price-to-Owner-Earnings ratio of Anhui Wanbang Pharmaceutical Technology Co was 53.12. The lowest was 0.00. And the median was 0.00.


SZSE:301520's Price-to-Owner-Earnings is ranked worse than
64.99% of 417 companies
in the Drug Manufacturers industry
Industry Median: 27.13 vs SZSE:301520: 37.17

Anhui Wanbang Pharmaceutical Technology Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ¥0.45. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1.83. It's PE Ratio ratio for today is 24.64.

Anhui Wanbang Pharmaceutical Technology Co's EPS without NRI for the three months ended in Mar. 2024 was ¥0.36. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1.72. It's PE Ratio without NRI ratio for today is 26.19.


Anhui Wanbang Pharmaceutical Technology Co Owner Earnings per Share (TTM) Historical Data

The historical data trend for Anhui Wanbang Pharmaceutical Technology Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anhui Wanbang Pharmaceutical Technology Co Owner Earnings per Share (TTM) Chart

Anhui Wanbang Pharmaceutical Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - 1.20 -

Anhui Wanbang Pharmaceutical Technology Co Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anhui Wanbang Pharmaceutical Technology Co's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Anhui Wanbang Pharmaceutical Technology Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anhui Wanbang Pharmaceutical Technology Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anhui Wanbang Pharmaceutical Technology Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Anhui Wanbang Pharmaceutical Technology Co's Price-to-Owner-Earnings falls into.



Anhui Wanbang Pharmaceutical Technology Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Anhui Wanbang Pharmaceutical Technology Co does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Anhui Wanbang Pharmaceutical Technology Co Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Traded in Other Exchanges
N/A
Address
southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000
Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines